Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholestatic syndromes.

Michael Trauner1, James L Boyer

  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Austria.

Current Opinion in Gastroenterology
|February 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Utility of Elastography in Discriminating Stages of Liver Fibrosis and Risk Stratification in Patients With Primary Sclerosing Cholangitis: A Systematic Review.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study.

Alimentary pharmacology & therapeutics·2026
Same author

Conjugated bile acid-driven CD14<sup>+</sup>CD16<sup>+</sup> monocyte infiltration promotes cholestatic liver injury by enhancing hepatocyte necroptosis.

JHEP reports : innovation in hepatology·2025
Same author

Liver Lymphatic Dysfunction as a Driver of Fibrosis and Cirrhosis Progression.

bioRxiv : the preprint server for biology·2025
Same author

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Hepatology communications·2024
Same author

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.

Cells·2024
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
Same journal

Retrograde cricopharyngeus dysfunction: what the gastroenterologist should know.

Current opinion in gastroenterology·2026
See all related articles

Recent advances in cholestasis research reveal new therapeutic targets like FXR ligands and identify novel genetic and environmental causes for liver diseases. This improves understanding and management of cholestatic disorders.

Area of Science:

  • Hepatology
  • Molecular Pathogenesis
  • Clinical Gastroenterology

Background:

  • Cholestasis encompasses a range of clinical disorders characterized by impaired bile flow.
  • Understanding the molecular mechanisms underlying cholestasis is crucial for effective treatment.

Purpose of the Study:

  • To review recent developments in the molecular pathogenesis of cholestasis.
  • To highlight new aspects of pathogenesis and management for clinical cholestatic disorders.

Main Methods:

  • Literature review of recent scientific publications.
  • Synthesis of findings on molecular mechanisms, genetic factors, and therapeutic targets.
  • Analysis of clinical studies across various cholestatic syndromes.

Main Results:

Related Experiment Videos

  • Identification of nuclear receptors, such as FXR ligands, as potential therapeutic agents.
  • Discovery of new genetic defects contributing to pediatric cholestasis and sclerosing cholangitis.
  • Emergence of novel infections and environmental agents as etiologies for primary biliary cirrhosis.
  • Review of significant clinical studies on pediatric cholestatic syndromes, intrahepatic cholestasis of pregnancy, primary biliary cirrhosis, sclerosing cholangitis, cholestasis of sepsis, viral cholestatic syndromes, and drug-induced cholestasis.

Conclusions:

  • Recent advances enhance the understanding of cholestatic liver disease pathophysiology.
  • Improved diagnostic approaches and management strategies are emerging.
  • Targeted therapies, informed by molecular insights, show promise for treating cholestatic disorders.